EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to intense sweeteners and contribution to the maintenance or achievement of a normal body weight (ID 1136, 1444, 4299), reduction of post-prandial glycaemic responses (ID 4298), maintenance of normal blood glucose concentrations (ID 1221, 4298), and maintenance of tooth mineralisation by decreasing tooth demineralisation (ID 1134, 1167, 1283) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 19, 2017
EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to intense sweeteners and contribution to
the maintenance or achievement of a normal body weight (ID 1136, 1444, 4299),
reduction of post-prandial glycaemic responses (ID 4298), maintenance of normal
blood glucose concentrations (ID 1221, 4298), and maintenance of tooth mineralisation
by decreasing tooth demineralisation (ID 1134, 1167, 1283) pursuant to Article 13(1) of
Regulation (EC) No 1924/2006
EFSA Publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2011.2229
Publication date:
2011
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2011). EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on
the substantiation of health claims related to intense sweeteners and contribution to the maintenance or
achievement of a normal body weight (ID 1136, 1444, 4299), reduction of post-prandial glycaemic responses (ID
4298), maintenance of normal blood glucose concentrations (ID 1221, 4298), and maintenance of tooth
mineralisation by decreasing tooth demineralisation (ID 1134, 1167, 1283) pursuant to Article 13(1) of
Regulation (EC) No 1924/2006. Parma, Italy: European Food Safety Authority.  (The EFSA Journal; No. 2229).
DOI: 10.2903/j.efsa.2011.2229
  EFSA Journal 2011;9(6):2229 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on the 
substantiation of health claims related to intense sweeteners and contribution to the maintenance or achievement of a normal 
body weight (ID 1136, 1444, 4299), reduction of post-prandial glycaemic responses (ID 4298), maintenance of normal blood 
glucose concentrations (ID 1221, 4298), and maintenance of tooth mineralisation by decreasing tooth demineralisation 
(ID 1134, 1167, 1283) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2229. [26 pp.]. 
doi:10.2903/j.efsa.2011.2229. Available online: www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2011 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to intense 
sweeteners and contribution to the maintenance or achievement of a 
normal body weight (ID 1136, 1444, 4299), reduction of post-prandial 
glycaemic responses (ID 4298), maintenance of normal blood glucose 
concentrations (ID 1221, 4298), and maintenance of tooth mineralisation by 
decreasing tooth demineralisation (ID 1134, 1167, 1283) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to intense sweeteners and contribution to the maintenance or achievement of a normal body 
weight, reduction of post-prandial glycaemic responses, maintenance of normal blood glucose 
concentrations, and maintenance of tooth mineralisation by decreasing tooth demineralisation. The 
scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The food constituents that are the subject of the health claims are intense sweeteners, which should 
replace sugars in foods and beverages in order to obtain the claimed effects. The Panel considers that 
intense sweeteners are sufficiently characterised in relation to the claimed effects. 
                                                     
1 On request from the European Commission, Question No EFSA-Q-2008-1873, EFSA-Q-2008-1875, EFSA-Q-2008-1906, 
EFSA-Q-2008-1959, EFSA-Q-2008-2021, EFSA-Q-2008-2181, EFSA-Q-2010-00251, EFSA-Q-2010-00252, adopted on 
08 April 2011. 
2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. One member of the Panel did not participate in the discussion 
on the subject referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on 
declarations of interests. 
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Contribution to the maintenance or achievement of a normal body weight  
The claimed effects are “weight management”, “weight control including weight loss”, and “intense 
sweeteners help to maintain a healthy body weight; intense sweeteners help to control calorie intake”. 
The target population is assumed to be the general population. The Panel considers that contribution 
to the maintenance or achievement of a normal body weight is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that data from both intervention and 
observational studies comparing high intakes of sugars (mainly as added sugars) to high intakes of 
starch with respect to weight gain are inconsistent, that epidemiological studies do not show a positive 
association between total sugar intake and obesity, and that three human intervention studies did not 
show an effect on body weight of replacing sugars by intense sweeteners in foods and beverages.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between total sugar intake and body weight gain, and that a cause and effect 
relationship has not been established between the consumption of foods and beverages in which 
sugars have been replaced by intense sweeteners and contribution to the maintenance or achievement 
of a normal body weight.  
Reduction of post-prandial glycaemic responses  
The claimed effect is “intense sweeteners have no effect on carbohydrate metabolism or short or long 
term blood glucose”. The target population is assumed to be individuals who wish to reduce their 
post-prandial glycaemic responses. In the context of the proposed wordings, the Panel assumes that 
the claimed effect refers to the reduction of post-prandial glycaemic responses. The Panel considers 
that the reduction of post-prandial glycaemic responses (as long as post-prandial insulinaemic 
responses are not disproportionally increased) may be a beneficial physiological effect. 
A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and reduction of post-prandial blood glucose 
responses has already been assessed with a favourable outcome. The Panel considers that the 
scientific substantiation and proposed conditions of use also apply to intense sweeteners.  
Maintenance of normal blood glucose concentrations  
The claimed effects are “blood glucose control” and “intense sweeteners have no effect on 
carbohydrate metabolism or short or long term blood glucose”. The target population is assumed to be 
the general population. In the context of the proposed wordings, the Panel assumes that the claimed 
effects refer to the maintenance of normal blood glucose concentrations. The Panel considers that 
maintenance of normal blood glucose concentrations is a beneficial physiological effect. 
No human intervention studies on the effects on long-term blood glucose control of replacing sucrose 
by intense sweeteners in a food, meal or diet, have been provided in the consolidated list.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of foods and beverages in which sugars have been replaced 
by intense sweeteners and maintenance of normal blood glucose concentrations.  
Maintenance of tooth mineralisation by decreasing tooth demineralisation  
The claimed effects are “dental health/sweeteners can not be fermented by oral bacteria, they are non-
cariogenic”, “foods which under typical conditions of use are neither cariogenic nor erosive, help 
maintain healthy teeth and are, therefore, toothfriendly”, and “dental health”. The target population is 
assumed to be the general population. In the context of the proposed wordings, conditions of use, and 
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references provided, the Panel assumes that the claimed effects refer to the maintenance of tooth 
mineralisation by decreasing tooth demineralisation. The Panel considers that maintaining tooth 
mineralisation by reducing tooth demineralisation resulting from acid production in plaque caused by 
the fermentation of carbohydrates is a beneficial physiological effect, provided that it is not 
accompanied by tooth demineralisation resulting from erosive properties of a food.  
A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and maintenance of tooth mineralisation by 
decreasing tooth demineralisation has already been assessed with a favourable outcome. The Panel 
considers that the scientific substantiation and proposed conditions of use also apply to intense 
sweeteners.  
KEY WORDS 
Intense sweeteners, body weight, post-prandial glycaemic responses, blood glucose, tooth, mineralisation, health 
claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituents that are the subject of the health claims are “table top sweeteners and foods 
beverages containing intense sweeteners”, “foods in general, in particular confectionery, soft 
beverages, water-ice, chocolate-type products, table-top sweeteners and certain foods for a particular 
nutritional use”, “foods in general, particularly sugar-free chewing gum, candies, chocolate-type 
products and other confectionery; soft beverages and sports beverages, flavored water and table top 
sweeteners”, “aspartame sucrose substitute”, and “low calorie sweetener / table-top sweetener 
(granular & tablets - sucralose based)”. 
In the context of the proposed wordings and conditions of use, the Panel assumes that the food 
constituent that is the subject of the health claims is intense sweeteners, which should replace sugars 
in foods and beverages in order to obtain the claimed effects. 
Intense sweeteners are substances with an intense sweet taste and with no energy value that are used 
to replace sugars in foods. Intense sweeteners (e.g. acesulfame K; aspartame; cyclamic acid and its 
sodium and calcium salts; saccharin and its sodium, potassium and calcium salts; sucralose; 
neohesperidine DC and thaumatin) vary in their chemical composition. This evaluation applies to the 
intense sweeteners authorised for addition to foods (Annex of Directive 94/35/EC
6
), according to 
Regulation (EC) No 1333/2008
7
. Intense sweeteners can be measured in foods by established 
methods. 
The Panel considers that the food constituents, intense sweeteners, which are the subject of the health 
claims, are sufficiently characterised in relation to the claimed effects. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 Directive 94/35/EC of the European Parliament and Council of 30 June 1994 on sweeteners for use in foodstuffs. OJ L 
237, 10.9.1994, p. 3-12. 
7 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. 
OJ L 354, 31.12.2008, p. 16-33. 
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2. Relevance of the claimed effect to human health 
2.1. Contribution to the maintenance or achievement of a normal body weight (ID 1136, 
1444, 4299) 
The claimed effects are “weight management”, “weight control including weight loss”, and “intense 
sweeteners help to maintain a healthy body weight; intense sweeteners help to control calorie intake”. 
The Panel assumes that the target population is the general population. 
Weight management can be interpreted as the contribution to maintenance of a normal body weight. 
In this context, weight loss in overweight individuals without achieving a normal body weight is 
considered to be a beneficial physiological effect.  
The Panel considers that contribution to the maintenance or achievement of a normal body weight is a 
beneficial physiological effect. 
2.2. Reduction of post-prandial glycaemic responses (ID 4298)  
The claimed effect is “intense sweeteners have no effect on carbohydrate metabolism or short or long 
term blood glucose”. The Panel assumes that the target population is individuals who wish to reduce 
their post-prandial glycaemic responses. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
reduction of post-prandial glycaemic responses.  
Post-prandial glycaemia is interpreted as the elevation of blood glucose concentrations after 
consumption of a food and/or meal. This elevation is a normal physiological response that varies in 
magnitude and duration, and which may be influenced by the chemical and physical nature of the food 
or meal consumed, as well as by individual factors (Venn and Green, 2007). Reducing post-prandial 
glycaemic responses may be beneficial to subjects with, for example, impaired glucose tolerance as 
long as post-prandial insulinaemic responses are not disproportionally increased. Impaired glucose 
tolerance is common in the general adult population. 
The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
2.3. Maintenance of normal blood glucose concentrations (ID 1221, 4298) 
The claimed effects are “blood glucose control” and “intense sweeteners have no effect on 
carbohydrate metabolism or short or long term blood glucose”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal blood glucose concentrations. 
The Panel considers that maintenance of normal blood glucose concentrations is a beneficial 
physiological effect. 
2.4. Maintenance of tooth mineralisation by decreasing tooth demineralisation (ID 1134, 
1167, 1283) 
The claimed effects are “dental health/sweeteners can not be fermented by oral bacteria, they are non-
cariogenic”, “foods which under typical conditions of use are neither cariogenic nor erosive, help 
Intense sweeteners related health claims 
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maintain healthy teeth and are, therefore, toothfriendly”, and “dental health”. The Panel assumes that 
the target population is the general population.  
In the context of the proposed wordings, conditions of use, and references provided, the Panel 
assumes that the claimed effects refer to the maintenance of tooth mineralisation by decreasing tooth 
demineralisation.  
Demineralisation of tooth tissues can occur following acid production caused by the fermentation of 
carbohydrates by acid-producing bacteria in dental biofilms. The effect may be balanced by 
remineralisation when pH is neutralised and a state of calcium and phosphate supersaturation is 
achieved. If demineralisation is not balanced by remineralisation then net demineralisation of tooth 
tissues results which, if sustained, can lead to dental caries. Demineralisation of tooth tissues can also 
occur as a result of consumption of dietary acids in foods or beverages, and frequent consumption can 
lead to dental erosion. Dental caries and dental erosion are diseases with a high prevalence in the EU. 
The Panel considers that maintaining tooth mineralisation by reducing tooth demineralisation 
resulting from acid production in plaque caused by the fermentation of carbohydrates is a beneficial 
physiological effect, provided that it is not accompanied by tooth demineralisation resulting from 
erosive properties of a food.  
3. Scientific substantiation of the claimed effect 
3.1. Contribution to the maintenance or achievement of a normal body weight (ID 1136, 
1444, 4299) 
The evidence provided by consensus opinions/reports from authoritative bodies and by reviews shows 
that data from both intervention and observational studies comparing high intakes of sugars (mainly 
as added sugars) to high intakes of starch with respect to weight gain is inconsistent (IoM, 2005; van 
Dam and Seidell, 2007), and that epidemiological studies do not show a positive association between 
total sugar intake and obesity (IoM, 2005). 
The references provided for the scientific substantiation of the claim included five narrative reviews 
on the effects of intense sweeteners as sugar replacers on satiety, food intake, body weight and safety 
aspects which did not provide original data for the scientific substantiation of the claim (Bellisle and 
Drewnowski, 2007; Benton, 2005; Gougeon et al., 2004; Renwick, 1994; Vermunt et al., 2003).  
One systematic review and meta-analysis of 16 intervention studies on the effects of intense 
sweeteners (i.e. mainly aspartame) as sugar replacers on satiety, energy intake and body weight (de la 
Hunty et al., 2006) was provided. These references contained all of the human intervention studies 
submitted individually in the consolidated list.  
The meta-analysis by de la Hunty et al. (2006) included a total of 16 studies, of which only 10 had 
body weight changes as an outcome (Blackburn et al., 1997; Gatenby et al., 1997; Kanders et al., 
1988; 1990; Naismith and Rhodes, 1995; Porikos et al., 1977; 1982; Raben et al., 2002; Reid and 
Hammersley, 1998; Tordoff and Alleva, 1990). These studies evaluated the effects of replacing 
sucrose with aspartame or other artificial sweeteners (Gatenby et al., 1997; Raben et al., 2002) in 
solid foods and/or beverages on body weight changes in the context of hypocaloric diets or of no 
energy restrictions. The Panel notes that in four of the studies (Naismith and Rhodes, 1995; Porikos et 
al., 1977; 1982; Reid and Hammersley, 1998) the study duration was between 7 and 12 days, which is 
too short to assess the effects of the intervention on sustained changes in body weight. In addition, 
some human intervention studies investigated the effect of replacing sugars with artificial sweeteners 
in beverages only. The Panel considers that no conclusions can be drawn from these studies, and 
therefore from the meta-analysis, for the scientific substantiation of the claim.  
Intense sweeteners related health claims 
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Three human intervention studies examined the effects of replacing sugars with artificial sweeteners 
in foods and beverages for 10 weeks or longer on body weight in overweight or obese subjects 
(Gatenby et al., (1997); Kanders et al., (1988) Blackburn et al., (1997)). 
In the study by Gatenby et al. (1997), overweight male and female subjects not using reduced-fat (RF) 
or reduced-sugar (RS) food products were assigned to consume their usual diet (n=18), a diet where 
full-fat foods were replaced by reduced-fat foods (RF, n=22), or a diet where conventional 
sucrose-containing foods were replaced by reduced-sucrose (artificially sweetened) foods (RS, n=25), 
for 10 weeks after a two-week run-in period. Data analysis was based on the population of completers 
for which appropriate dietary intake data were available (13, 17 and 19 for control, RF and RS groups, 
respectively). Post-hoc power calculations led to a power of 90 % to observe a between-group 
difference in body weight changes of 0.4 kg. Subjects in the RF group significantly reduced fat intake 
compared to the RS and control groups (p=0.017), whereas subjects in the RS group significantly 
reduced sucrose intake compared to the RF and control groups (p=0.049). No differences between 
groups were observed with respect to energy intake or changes in body weight. Whether reduced 
sucrose items replaced solid foods, beverages, or both, and to what extent, was not reported. The 
Panel notes that this study does not show a differential effect on body weight of sucrose-sweetened 
foods and beverages vs. reduced (artificially sweetened) sucrose foods and beverages. 
The study by Kanders et al. (1988) was designed to assess the effects of adding aspartame-sweetened 
foods and beverages to a low fat, hypocaloric diet for 12 weeks on compliance and weight loss. A 
total of 59 obese subjects (10 men) were randomised to consume aspartame-sweetened foods (e.g. 
puddings) and beverages (milkshakes, diet beverages), or to abstain from them, during 12 weeks in 
the context of a low-energy diet for weight loss. Changes in body weight did not differ significantly 
between groups for either males or females (results for the whole study sample combined were not 
provided). The Panel notes that this study does not show a differential effect on body weight of 
sucrose-sweetened foods and beverages vs. reduced (artificially sweetened) sucrose foods and 
beverages. In an abstract published two years later, Kanders et al. (1990) reported on the 46 subjects 
who participated in a 12-month weight maintenance period after the 12-week intervention. The Panel 
notes that this weight maintenance phase was not controlled for aspartame intake, that comparisons 
between intervention and control groups were not reported, that body weight changes were not 
reported, and that details on the statistical analysis used were not provided. The Panel considers that 
no conclusions can be drawn from the weight maintenance phase of this study for the scientific 
substantiation of the claim.  
In a study by Blackburn et al. (1997), 163 obese women were randomised to either consume or abstain 
(control) from aspartame-sweetened foods and beverages during 16 weeks of a 19-week 
multidisciplinary weight loss program, a one-year maintenance program, and a two-year follow-up 
period. The no aspartame group was asked to use up to 50 g of sugar or honey as daily sweetener. No 
differences in body weight loss were observed between the aspartame and control groups during the 
active weight loss phase (-9.9 6.1 kg vs. -9.8 6.5, corresponding to about -10 % of initial body 
weight in both groups). During the weight maintenance phase, the aspartame group regained less 
weight than the control group (2.6 % vs. 5.4 % of initial body weight). Although a direct statistical 
comparison between groups is not reported in this paper, the meta-analysis by de la Hunty et al. 
(2006) reported no statistically significant differences between groups (p=0.143). When all study 
participants were considered together, a greater percentage of weight loss from baseline was predicted 
by randomisation to the aspartame group (p=0.05), but percentage weight loss was positively 
correlated with physical exercise (r=0.32, p=0.005) and self-reported eating control (r=0.37, 
p=0.0001), rather than with aspartame intake (r=0.19, p=0.07). As reported physical exercise and 
energy intake was not different between groups, the differences observed in body weight changes are 
difficult to explain. However, the Panel notes that dietary records in overweight subjects are not 
reliable to assess energy intake as they tend to closely report prescribed energy intakes. The Panel 
notes that the later phase (i.e after follow-up) of the study was uncontrolled. During the study, no 
Intense sweeteners related health claims 
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differences were found between groups with respect to desire for sweets or hunger. Whether 
aspartame consumption replaced sugar predominantly in foods or in beverages, and to what extent, is 
not reported. The Panel notes that this study does not support a differential effect on body weight of 
sucrose-sweetened foods and beverages vs. reduced (artificially sweetened) sucrose foods and 
beverages.  
The Panel notes that three human intervention studies did not show an effect of replacing sugars by 
artificial sweeteners in foods and beverages on body weight in overweight and obese subjects, and 
that no studies which addressed the effects of replacing sugars by artificial sweeteners in foods and 
beverages on body weight in normal weight subjects were provided.  
There is some evidence from epidemiological and intervention studies that high intake of sugars in the 
form of sugar-sweetened beverages might contribute to body weight gain (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2010). However, the Panel notes that the effect on body 
weight of replacing sugars by intense sweeteners in beverages only is not the subject of the health 
claim evaluated in this opinion.  
In weighing the evidence, the Panel took into account that data from both intervention and 
observational studies comparing high intakes of sugars (mainly as added sugars) to high intakes of 
starch with respect to weight gain is inconsistent, that epidemiological studies do not show a positive 
association between total sugar intake and obesity, and that three human intervention studies did not 
show an effect on body weight of replacing sugars by intense sweeteners in foods and beverages.  
The Panel concludes that a cause and effect relationship has not been established between total sugar 
intake and body weight gain, and that a cause and effect relationship has not been established between 
the consumption of foods and beverages in which sugars have been replaced by intense sweeteners 
and contribution to the maintenance or achievement of a normal body weight.  
3.2. Reduction of post-prandial blood glucose responses (ID 4298) 
A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and reduction of post-prandial blood glucose 
responses has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2011).  
The Panel considers that the scientific substantiation and proposed conditions of use also apply to 
intense sweeteners.  
3.3. Maintenance of normal blood glucose concentrations (ID 1221, 4298) 
Some of the references provided for the scientific substantiation of the claim reported on human 
intervention studies which were unrelated to the claimed effect, (i.e. assessed the effects of sucralose 
on post-prandial blood glucose responses). The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim.  
One human study investigated the effect of a modified diet containing both a fat replacer (beta-glucan 
derived from oats) and the intense sweetener sucralose compared to a diet containing fructose on 
blood glucose concentrations (Reyna et al., 2003). The Panel considers that no conclusions can be 
drawn from this study for the scientific substantiation of a claim on intense sweeteners alone. 
In the study by Cooper et al. (1988), the effects of a usual diet for blood glucose control supplemented 
with either 28 g sucrose (sucrose diet) or with 30 g starch and saccharin (saccharin diet) for six weeks 
each on fasting blood glucose and insulin concentrations were assessed in 17 non-insulin dependent 
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diabetic patients following a randomised, cross-over design. The Panel notes that fasting blood 
glucose and insulin concentrations are not appropriate outcome measures of long-term blood glucose 
control. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
In the study by Grotz et al. (2003), 128 subjects with type 2 diabetes were randomly assigned to 
receive either placebo (cellulose) capsules (n=69) or 667 mg encapsulated sucralose (n=67) daily for 
13 weeks. Glycated haemoglobin (HbA1c), fasting plasma glucose and fasting serum C-peptide were 
measured approximately every two weeks to evaluate blood glucose homeostasis. The Panel notes that 
in this study sucralose was compared to cellulose, and that such comparison does not allow drawing 
conclusions on the effect of replacing sugar (sucrose) with sucralose on the maintenance of normal 
blood glucose concentrations. 
The evidence provided by consensus opinions/reports from authoritative bodies and by reviews shows 
that consumption of intense sweeteners in the diet in replacement of sucrose at the amounts likely to 
be consumed in a meal or day is unlikely to have an impact on blood glucose control in diabetic 
subjects (American Diabetes Association, 2002; Gougeon et al., 2004).  
No human intervention studies on the effects on long-term blood glucose control of replacing sucrose 
with intense sweeteners in a food, meal or diet have been provided in the consolidated list.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of foods and beverages in which sugars have been replaced by intense sweeteners and 
maintenance of normal blood glucose concentrations.  
3.4. Maintenance of tooth mineralisation by decreasing tooth demineralisation (ID 1134, 
1167, 1283) 
A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and maintenance of tooth mineralisation by 
decreasing tooth demineralisation has already been assessed with a favourable outcome (EFSA Panel 
on Dietetic Products Nutrition and Allergies (NDA), 2011).  
The Panel considers that the scientific substantiation and proposed conditions of use also apply to 
intense sweeteners.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituents that are the subject of the health claims are intense sweeteners, which 
should replace sugars in foods and beverages in order to obtain the claimed effects. Intense 
sweeteners are sufficiently characterised in relation to the claimed effects. 
Contribution to the maintenance or achievement of a normal body weight (ID 1136, 1444, 4299) 
 The claimed effects are “weight management”, “weight control including weight loss”, and 
“intense sweeteners help to maintain a healthy body weight; intense sweeteners help to 
control calorie intake”. The target population is assumed to be the general population. 
Contribution to the maintenance or achievement of a normal body weight is a beneficial 
physiological effect. 
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 A cause and effect relationship has not been established between total sugar intake and body 
weight gain, and a cause and effect relationship has not been established between the 
consumption of foods and beverages in which sugars have been replaced by intense 
sweeteners and contribution to the maintenance or achievement of a normal body weight. 
Reduction of post-prandial glycaemic responses (ID 4298) 
 The claimed effect is “intense sweeteners have no effect on carbohydrate metabolism or short 
or long term blood glucose”. The target population is assumed to be individuals who wish to 
reduce their post-prandial glycaemic responses. In the context of the proposed wordings, it is 
assumed that the claimed effect refers to the reduction of post-prandial glycaemic responses. 
Reduction of post-prandial glycaemic responses (as long as post-prandial insulinaemic 
responses are not disproportionally increased) may be a beneficial physiological effect. 
 A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and reduction of post-prandial 
glycaemic responses has already been assessed with a favourable outcome. The scientific 
substantiation and proposed conditions of use also apply to intense sweeteners.  
Maintenance of normal blood glucose concentrations (ID 1221, 4298) 
 The claimed effects are “blood glucose control” and “intense sweeteners have no effect on 
carbohydrate metabolism or short or long term blood glucose”. The target population is 
assumed to be the general population. Maintenance of normal blood glucose concentrations is 
a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of foods 
and beverages in which sugars have been replaced by intense sweeteners and maintenance of 
normal blood glucose concentrations.  
Maintenance of tooth mineralisation by decreasing tooth demineralisation (ID 1134, 1167, 1283) 
 The claimed effects are “dental health/sweeteners can not be fermented by oral bacteria, they 
are non-cariogenic”, “foods which under typical conditions of use are neither cariogenic nor 
erosive, help maintain healthy teeth and are, therefore, toothfriendly”, and “dental health”. 
The target population is assumed to be the general population. Maintaining tooth 
mineralisation by reducing tooth demineralisation resulting from acid production in plaque 
caused by the fermentation of carbohydrates is a beneficial physiological effect, provided that 
it is not accompanied by tooth demineralisation resulting from erosive properties of a food.  
 A claim on the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, 
D-tagatose, isomaltulose, sucralose and polydextrose and maintenance of tooth mineralisation 
by decreasing tooth demineralisation has already been assessed with a favourable outcome. 
The scientific substantiation and proposed conditions of use also apply to intense sweeteners.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1873, 
EFSA-Q-2008-1875, EFSA-Q-2008-1906, EFSA-Q-2008-1959, EFSA-Q-2008-2021, EFSA-Q-2008-
2181, EFSA-Q-2010-00251, EFSA-Q-2010-00252). The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
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The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
American Diabetes Association, 2002. Evidence-based nutrition principles and recommendations for 
the treatment and prevention of diabetes and related complications. Diabetes Care, 25(Supp 1), 
S50-60. 
Bellisle F and Drewnowski A, 2007. Intense sweeteners, energy intake and the control of body 
weight. European Journal of Clinical Nutrition, 61, 691-700. 
Benton D, 2005. Can artificial sweeteners help control body weight and prevent obesity? Nutrition 
Research Reviews, 18, 63-76. 
Blackburn GL, Kanders BS, Lavin PT, Keller SD and Whatley J, 1997. The effect of aspartame as 
part of a multidisciplinary weight-control program on short- and long-term control of body weight. 
American Journal of Clinical Nutrition, 65, 409-418. 
Cooper PL, Wahlqvist ML and Simpson RW, 1988. Sucrose versus saccharin as an added sweetener 
in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine, 
5, 676-680. 
de la Hunty A, Gibson S and Ashwell M, 2006. A review of the effectiveness of aspartame in helping 
with weight control. British Nutrition Foundation Nutrition Bulletin, 31, 115-128. 
EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on Dietary 
Reference Values for carbohydrates and dietary fibre. EFSA Journal 8(3):1462, 5 pp. 
EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011. Scientific Opinion on the 
substantiation of health claims related to the sugar replacers xylitol, sorbitol, mannitol, maltitol, 
lactitol, isomalt, erythritol, D-tagatose, isomaltulose, sucralose and polydextrose and maintenance 
of tooth mineralisation by decreasing tooth demineralisation (ID 463, 464, 563, 618, 647, 1182, 
1591, 2907, 2921, 4300), and reduction of post prandial glycaemic responses (ID 617, 619, 669, 
1590, 1762, 2903, 2908, 2920) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 9(4):2076, 25 pp. 
Gatenby SJ, Aaron JI, Jack VA and Mela DJ, 1997. Extended use of foods modified in fat and sugar 
content: nutritional implications in a free-living female population. American Journal of Clinical 
Nutrition, 65, 1867-1873. 
Gougeon R, Spidel M, Lee K and Field CJ, 2004. Canadian Diabetes Association National Nutrition 
Committee Technical Review: Non-nutritive intense sweeteners in diabetes management. 
Canadian Journal of Diabetes, 28, 385-399. 
Grotz VL, Henry RR, McGill JB, Prince MJ, Shamoon H, Trout JR and Pi-Sunyer FX, 2003. Lack of 
effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the 
American Dietetic Association, 103, 1607-1612. 
IoM (Institute of Medicine), 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, 
Fatty acids, Cholesterol, Protein, and Amino Acids. National Academies Press, Washington DC. 
Kanders BS, Lavin PT, Kowalchuk MB, Greenberg I and Blackburn GL, 1988. An evaluation of the 
effect of aspartame on weight loss. Appetite, 11 Suppl 1, 73-84. 
Kanders BS, Lavin JH, Kowalchuk MB and Blackburn GL, 1990. Do aspartame (APM) -sweetened 
foods and beverages in the long-term aid in long-term control of body weight? American Journal 
of Clinical Nutrition, 51, 515. 
Naismith DJ and Rhodes C, 1995. Adjustment in energy intake following the covert removal of sugar 
from the diet. Journal of Human Nutrition and Dietetics, 8, 167-175. 
Intense sweeteners related health claims 
 
14 EFSA Journal 2011;9(6):2229 
Porikos KP, Booth G and Van Itallie TB, 1977. Effect of covert nutritive dilution on the spontaneous 
food intake of obese individuals: a pilot study. American Journal of Clinical Nutrition, 30, 1638-
1644. 
Porikos KP, Hesser MF and van Itallie TB, 1982. Caloric regulation in normal-weight men maintained 
on a palatable diet of conventional foods. Physiology and Behavior, 29, 293-300. 
Raben A, Vasilaras TH, Moller AC and Astrup A, 2002. Sucrose compared with artificial sweeteners: 
different effects on ad libitum food intake and body weight after 10 wk of supplementation in 
overweight subjects. American Journal of Clinical Nutrition, 76, 721-729. 
Reid M and Hammersley R, 1998. The effects of blind substitution of aspartame-sweetened for sugar-
sweetened soft drinks on appetite and mood. British Food Journal, 100, 254-259. 
Renwick AG, 1994. Intense sweeteners, food intake, and the weight of a body of evidence. Physiology 
and Behavior, 55, 139-143. 
Reyna NY, Cano C, Bermudez VJ, Medina MT, Souki AJ, Ambard M, Nunez M, Ferrer MA and 
Inglett GE, 2003. Sweeteners and beta-glucans improve metabolic and anthropometrics variables 
in well controlled type 2 diabetic patients. American Journal of Therapeutics, 10, 438-443. 
Tordoff MG and Alleva AM, 1990. Effect of drinking soda sweetened with aspartame or high-
fructose corn syrup on food intake and body weight. American Journal of Clinical Nutrition, 51, 
963-969. 
van Dam RM and Seidell JC, 2007. Carbohydrate intake and obesity. European Journal of Clinical 
Nutrition, 61 Suppl 1, S75-99. 
Venn BJ and Green TJ, 2007. Glycemic index and glycemic load: measurement issues and their effect 
on diet-disease relationships. European Journal of Clinical Nutrition, 61 Suppl 1, S122-131. 
Vermunt SH, Pasman WJ, Schaafsma G and Kardinaal AF, 2003. Effects of sugar intake on body 
weight: a review. Obesity Reviews, 4, 91-99. 
 
 
Intense sweeteners related health claims 
 
15 EFSA Journal 2011;9(6):2229 
APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to intense sweeteners, including conditions of use from 
similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1134 Table top sweeteners and 
foods, beverages containing 
intense sweeteners 
Clarification provided 
Table top sweeteners (as 
defined in Regulation 
1333/2008*) and foods and 
beverages containing intense 
sweeteners**   
*Article 3.2(g) of Regulation 
(EC) 1333/2008 on food 
additives: "Table-top 
sweeteners shall mean 
preparations of permitted 
sweeteners, which may contain 
other food additives and/or 
food ingredients and which are 
intended for sale to the final 
consumer as a substitute for 
sugars."   
** Intense sweeteners as 
permitted for use in foodstuffs 
according to Directive 
94/35/EC. These include 
Acesulfame K, Aspartame, 
Cyclamic acid and its Na and 
Ca Salts, Saccharin and its Na, 
K and Ca salts, Sucralose  
OR 
Table top sweeteners and 
foods, beverages containing 
intense sweeteners: 
Food or beverage shall not 
lower plaque pH below 5,7 by 
bacterial fermentation during, 
and up to 30 min after 
consumption, as determined by 
plaque pH telemetry (US 
21CFR§101.80) or other 
comparable methods 
Dental health/ sweeteners 
can not be fermented by oral 
bacteria, they are non-
cariogenic. 
Intense sweetners are non-
cariogenic; intense sweeteners do 
not promote tooth decay; this 
table top sweetener is safe for 
teeth. 
Conditions of use 
- Food or beverage shal not lower plaque pH below 5,7 by bacterial fermentation during, and up 
to 30 min after consumption, as determined by plaque pH telemetry (US 21CFR§101.80) or 
other comparable methods. 
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ID Food or Food constituent Health Relationship Proposed wording 
1136 Table top sweeteners and foods 
beverages containing intense 
sweeteners 
Clarifications provided 
Table top sweeteners (as 
defined in Regulation 
1333/2008*) and foods and 
beverages containing intense 
sweeteners**   
*Article 3.2(g) of Regulation 
(EC) 1333/2008 on food 
additives: "Table-top 
sweeteners shall mean 
preparations of permitted 
sweeteners, which may contain 
other food additives and/or 
food ingredients and which are 
intended for sale to the final 
consumer as a substitute for 
sugars."   
** Intense sweeteners as 
permitted for use in foodstuffs 
according to Directive 
94/35/EC. These include 
Acesulfame K, Aspartame, 
Cyclamic acid and its Na and 
Ca Salts, Saccharin and its Na, 
K and Ca salts, Sucralose  
OR 
Table top sweeteners and 
foods, beverages containing 
intense sweeteners: 
Food or beverage shall not 
lower plaque pH below 5,7 by 
bacterial fermentation during, 
and up to 30 min after 
consumption, as determined by 
plaque pH telemetry (US 
21CFR§101.80) or other 
comparable methods 
Weight management -intense sweetners help to 
maintain a healthy body weight;  
-intense sweetners help to control 
calorie intake. 
Conditions of use 
- In an energy restricted diet 
ID Food or Food constituent Health Relationship Proposed wording 
1167 
 
 
Foods in general, in particular 
confectionery, soft beverages, 
water-ice, chocolate-type 
products, table-top sweeteners 
Foods which under typical 
conditions of use are neither 
cariogenic nor erosive, help 
maintain healthy teeth and 
Toothfriendly  [pictorial claim] 
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and certain foods for a 
particular nutritional use. 
Clarification provided 
'The toothfriendly trademark 
and the accompanying claim 
"toothfriendly" signifies that 
the respective food is not 
causing harm to the teeth. The 
claim is thus truthful for each 
consumed food that complies 
with the stated criteria, i.e. the 
claim is not tied to a specific 
ingredient of the food. Hence, 
there is no minimum amount of 
food required to achieve the 
claimed benefit and there is no 
dose-response relationship. 
are, therefore, toothfriendly. 
Conditions of use 
- "(a) Foods which, under usual conditions of consumption, do not lower the pH of the dental 
plaque below 5.7, are non-cariogenic (pH measurement in vivo in the interproximal space by 
means of an indwelling electrode) " "(b) Foods which, under usual conditions of consumption, 
do not expose the plaque-free tooth surface to more than 40 µmol H+ x min are non-erosive on 
the tooth surface (measurement in vivo with plaque-free electrode in the oral fluid) 
Only foods which comply with the criteria (a) and (b) are ""toothfriendly"".  
Sugarfree foods are not always and necessarily toothfriendly, because they may contain non-
sugar, fermentable carbohydrates or excessive amounts of food acids with an erosive effect. 
The claim ""toothfriendly"" (or similar expressions) can, therefore, not simply be tied to the 
absence of sugar or the presence of sugar substitutes (polyols). The toothfriendly property 
depends upon the food's overall composition and some other characteristics. Therefore, it is 
best tested for each food applying the standardized tests mentioned under (a) and (b) above.  
The toothfriendly property of a food is an inherent characteristic that does not depend upon the 
amount of food consumed." 
- The Happy Tooth symbol can be used in the packaging descriptions of products that do not 
cause cavities or damage tooth enamel.  
The symbol is often used by tooth-friendly products, but juices, sorbets and sweeteners can 
also meet the criteria. The symbol is only granted to products that 
a) do not lower the pH level of plaque below 5.7 in conjunction with normal use (pH is 
measured in vivo from the area between two teeth using an electrode attached to the tooth 
surface.  
b) do not expose the tooth enamel to more than 40 μmol H+ x min in conjunction with normal 
use (this is measured in vivo from the saliva using an electrode attached to the tooth surface). 
Only products that meet criteria a) and b) are tooth-friendly. 
Use of the symbol is not tied to a specific raw material in the products, such as xylitol. In 
theory, a product with added xylitol can be harmful to the teeth. 
Unsweetened products are not always and automatically tooth-friendly, because they can 
contain sugar-like carbohydrates that cause cavities. Similarly, foods can include large amounts 
of (lemon, etc.) acids, which have a wearing effect on tooth enamel. 
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The health claim “tooth-friendly” (or a similar claim) can not directly refer to the sugar-free 
nature of the product or to the presence of certain sweeteners added to the product, such as 
xylitol. The tooth-friendliness of foods is based on the product’s complete recipe and other 
properties (for example, size). 
- A standardised test based on criterion a) or b) and which is used by the faculties of dentistry at 
several European universities must be used to determine the tooth-friendliness of the product. 
ID Food or Food constituent Health Relationship Proposed wording 
1221 Table top sweeteners and foods 
beverages containing intense 
sweeteners 
Clarification provided 
Table top sweeteners (as 
defined in Regulation 
1333/2008*) and foods and 
beverages containing intense 
sweeteners**   
*Article 3.2(g) of Regulation 
(EC) 1333/2008 on food 
additives: "Table-top 
sweeteners shall mean 
preparations of permitted 
sweeteners, which may contain 
other food additives and/or 
food ingredients and which are 
intended for sale to the final 
consumer as a substitute for 
sugars."   
** Intense sweeteners as 
permitted for use in foodstuffs 
according to Directive 
94/35/EC. These include 
Acesulfame K, Aspartame, 
Cyclamic acid and its Na and 
Ca Salts, Saccharin and its Na, 
K and Ca salts, Sucralose  
Blood glucose control -intense sweeteners have no 
effect on carbohydrate 
metabolism, short or long-term 
blood glucose control or insulin 
secretion; 
-product [x] assists in blood 
glucose control. 
Conditions of use 
- Food has no significant impact on blood glcuose or insulin. 
ID Food or Food constituent Health Relationship Proposed wording 
1283 
 
 
 
 
 
 
Foods in general, particularly 
sugar-free chewing gum, 
candies, chocolate-type 
products and other 
confectionery; soft beverages 
and sports beverages, flavored 
water and table top sweeteners. 
Clarification provided 
Foods in general, particularly 
chewing gum, candies, 
Dental health Tooth friendly 
Tooth friendly logo 
Intense sweeteners related health claims 
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 chocolate-type products and 
other confectionery; soft 
beverages and sports 
beverages, flavored water and 
table top sweeteners. The food 
shall, under usual conditions of 
consumption (a) not lower the 
pH of the dental plaque below 
5.7 (pH measurement in vivo in 
the interproximal space by 
means of an indwelling 
electrode) and (b) not expose 
the plaque-free tooth surface to 
more than 40 μmol H+ x min 
(measurement in vivo with 
plaque-free electrode in the oral 
fluid). 
Conditions of use 
- The food shall, under usual condtions of consumption (a) not lower the pH of the dental plaque 
below 5.7 (pH measurement in vivo in the interproximal space by means of an indwelling 
electrode) and (b) not expose the plaque-free tooth surface to more than 40 µmol H+ x min 
(measurement in vivo with plaque-free electrode in the oral fluid). 
ID Food or Food constituent Health Relationship Proposed wording 
1444 Aspartame sucrose substitute Weight control, including 
weight loss 
Weight control /management is 
helped by using foods and 
beverages sweetened with 
Aspartame in place of foods and 
beverages sweetened with sugar. 
Conditions of use 
- Should be consumed as part of a calorie controlled diet. 
ID Food or Food constituent Health Relationship Proposed wording 
4298 
 
 
 
 
 
 
 
 
 
 
 
Name of Food product: Low 
Calorie Sweetener / Table-top 
Sweetener (Granular & tablets - 
sucralose based) 
Description of food in terms of 
food legislation categories: 
food not covered by specific 
food legislation 
Was food on Irish market 
before 1st July 2007: Yes 
Health benefits of food: 
intense sweeteners have no 
effect on carbohydrate 
metabolism or short or long 
term blood glucose 
Do benefits relate to a 
disease risk factor: No 
Target group: All of the 
general population including 
children and adults 
Exact wording of claim as it 
appears on product: Suitable for 
people with diabetes within their 
healthy dietary plan / as part of a 
healthy diet and lifestyle. 
Examples of any alternative 
wording that may be used in 
relation to claim: Splenda has no 
effect on carbohydrate 
metabolism or short or long term 
blood glucose 
Splenda low calorie sweetener 
has no effect on short or long 
term blood glucose or insulin 
secretion 
Splenda can assist in blood 
glucose control 
Intense sweeteners related health claims 
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 Is claim a picture: No 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 1. Names of 
nutrient/other substances and Quantity in Average daily serving: 0.1 grams Sucralose. Weight 
of average daily food serving:     1 gram. Daily amount to be consumed to produce claimed 
effect:     1 gram. Number of food portions this equates to in everyday food portions:     2. Are 
there factors that could interfere with bioavailability: No. Length of time after consumption for 
claimed effect to become apparent: benefits on use. Is there a limit to the amount of food which 
should be consumed in order to avoid adverse health effects: Yes. State the maximum limit in 
mg/kg body weight/day:    15.00. Potential adverse health effects: N/A It is extremely unlikely 
that consumer would exceed the ADI. see FSAI report on intake). Describe subgroups this limit 
applies to: all sub groups. Where applicable outline nutritional composition (g per 100g) of 
food: Total Fat:      .00, Saturated Fat:      .00, Trans Fat:      .00, Sugar:     6.90, Salt:      .00, 
Sodium:      .00. Other conditions for use: Food has no significant effect on blood glucose or 
insulin 
ID Food or Food constituent Health Relationship Proposed wording 
4299 Name of Food product: Low 
Calorie Sweetener / Table-top 
Sweetener (Granular & tablets - 
sucralose based) 
Description of food in terms of 
food legislation categories: 
food not covered by specific 
food legislation 
Was food on Irish market 
before 1st July 2007: Yes 
Health benefits of food: 
intense sweeteners help to 
maintain a healthy body 
weight; intense sweeteners 
help to control calorie intake 
Do benefits relate to a 
disease risk factor: No 
Target group: All of the 
general population including 
children and adults 
Exact wording of claim as it 
appears on product: Splenda can 
help with slimming as part of a 
calorie controlled diet.   
Splenda is also suitable for those 
following a low carbohydrate 
diet. In France, 'peut contributer 
a une reduction de l'apport 
calorique quotidien' 
Examples of any alternative 
wording that may be used in 
relation to claim: Splenda low 
calorie sweetener can help to 
maintain a healthy body weight 
as part of a calorie-controlled 
diet. Splenda low calorie 
sweetener helps to control calorie 
intake as part of a calorie 
controlled diet. 
Is claim a picture: No 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 1. Names of 
nutrient/other substances and Quantity in Average daily serving: 0.1 gram sucralose. Weight of 
average daily food serving:     1 gram. Daily amount to be consumed to produce claimed effect:     
1 gram. Number of food portions this equates to in everyday food portions:     2. Are there 
factors that could interfere with bioavailability: No. Length of time after consumption for 
claimed effect to become apparent: Benefits on use. Is there a limit to the amount of food which 
should be consumed in order to avoid adverse health effects: Yes. State the maximum limit in 
mg/kg body weight/day:    15.00. Potential adverse health effects: N/A It is extremely unlikely 
that a consumer would exceed the ADI (see FSAI report on intake). Describe subgroups this 
limit applies to: all sub groups. Where applicable outline nutritional composition (g per 100g) of 
food: Total Fat:      .00, Saturated Fat:      .00, Trans Fat:      .00, Sugar:     6.90, Salt:      .00, 
Sodium:      .00. Other conditions for use: requires a calorie controlled diet 
Intense sweeteners related health claims 
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GLOSSARY AND ABBREVIATIONS 
HbA1c  Glycated haemoglobin 
RF  Reduced-fat  
RS  Reduced-sugar  
